Figure 4 | Scientific Reports

Figure 4

From: Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway

Figure 4The alternative text for this image may have been generated using AI.

MAPK14 expression in STAD patients based on patients’ characteristics. (A) MAPK14 expression in total STAD. (B) MAPK14 expression in STAD based on patient’s gender. (C) MAPK14 expression in STAD based on patient’s age. (D) MAPK14 expression in STAD based on individual cancer stages. (E) MAPK14 expression in STAD based on tumor grade. (F) MAPK14 expression in STAD based on histological subtypes. (G) MAPK14 expression in STAD based on nodal metastasis status. (H) MAPK14 expression in STAD based on H. pylori infection status. (I) MAPK14 expression in STAD based on TP53 mutation status.

Back to article page